---
title: "LeonaBio (LONA) news: reverse split"
url: "https://aibio.space/companies/leonabio/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "LONA reverse split news: Athira Pharma (now LeonaBio) wins Nasdaq Capital Market move and 180 more days. LeonaBio, Inc. (NASDAQ: LONA), United States."
---

LONA LeonaBio, Inc. NASDAQ · United States

# LeonaBio (LONA) news LONA reverse split news

Financings · 2026-09-22

## [LeonaBio Series A warrants become exercisable at $6.35 a share](https://aibio.space/news/leonabio-series-warrants-become-exercisable-6-35-share/)

LeonaBio said its Series A common warrants became exercisable on September 18, 2026 and remain exercisable until October 19, 2026, with about $146.2 million of cash if fully exercised.

## Latest LeonaBio news

1. 2026-08-26 Financings [LeonaBio enrolls 500th subject in Phase 3 ELAINE-3 trial](https://aibio.space/news/leonabio-enrolls-500th-subject-phase-3-elaine-3-trial/) LeonaBio said it enrolled the 500th subject in its ELAINE-3 trial of lasofoxifene, an announcement that also sets a date used in the exercise terms of its Series A warrants.
2. 2026-08-14 Company Updates [LeonaBio reports second quarter 2026 results and ELAINE-3 update](https://aibio.space/news/leonabio-reports-second-quarter-2026-results-elaine-3-update/) LeonaBio reported cash, cash equivalents and investments of $51.1 million at June 30, 2026, and said it has enrolled 495 patients in its Phase 3 ELAINE-3 trial.
3. 2026-05-07 Company Updates [LeonaBio reports first quarter 2026 results and ELAINE-3 amendment](https://aibio.space/news/leonabio-reports-first-quarter-2026-results-elaine-3-amendment/) LeonaBio said it is increasing the ELAINE-3 sample size to up to 600 participants and expects to start a Phase 2 ALS study for ATH-1105 in the second half of 2026.
4. 2025-04-16 Listings [Athira Pharma (now LeonaBio) wins Nasdaq Capital Market move and 180 more days](https://aibio.space/news/athira-pharma-now-leonabio-wins-nasdaq-capital-market-move-180-more/) The transfer takes effect April 17, 2025. Athira, now LeonaBio, has until October 13, 2025 to lift its stock to $1.00 and is seeking approval for a reverse split.

## LeonaBio at a glance

- **Ticker**: LONA

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $51.1 million

### Related companies

- [Range Impact](https://aibio.space/companies/range-impact/) OTC: RNGE
- [BioCardia](https://aibio.space/companies/biocardia/) NASDAQ: BCDA
- [InVitro International](https://aibio.space/companies/invitro-international/) OTC: IVRO
- [Altimmune](https://aibio.space/companies/altimmune/) NASDAQ: ALT
- [Aridis Pharmaceuticals](https://aibio.space/companies/aridis-pharmaceuticals/) OTC: ARDS
- [Disc Medicine](https://aibio.space/companies/disc-medicine/) NASDAQ: IRON
- [Aditxt](https://aibio.space/companies/aditxt/) OTC: ADTX
- [Coya Therapeutics](https://aibio.space/companies/coya-therapeutics/) NASDAQ: COYA

### Also on NASDAQ

- [Redhill Biopharma](https://aibio.space/companies/redhill-biopharma/) RDHL
- [Prime Medicine](https://aibio.space/companies/prime-medicine/) PRME
- [LB Pharmaceuticals](https://aibio.space/companies/lb-pharmaceuticals/) LBRX
- [Krystal Biotech](https://aibio.space/companies/krystal-biotech/) KRYS
- [Denali Therapeutics](https://aibio.space/companies/denali-therapeutics/) DNLI
- [Alumis](https://aibio.space/companies/alumis/) ALMS

## LeonaBio annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$17.5 million](https://www.sec.gov/Archives/edgar/data/1620463/000119312526134565/) | [$70.7 million](https://www.sec.gov/Archives/edgar/data/1620463/000119312526134565/) |
| Net income (loss) | [-$105.6 million](https://www.sec.gov/Archives/edgar/data/1620463/000119312526134565/) | [-$96.9 million](https://www.sec.gov/Archives/edgar/data/1620463/000119312526134565/) |
| Cash from operations | [-$45.7 million](https://www.sec.gov/Archives/edgar/data/1620463/000119312526134565/) | [-$97.2 million](https://www.sec.gov/Archives/edgar/data/1620463/000119312526134565/) |
| Cash and equivalents | [$69.3 million](https://www.sec.gov/Archives/edgar/data/1620463/000119312526352243/) | [$48.4 million](https://www.sec.gov/Archives/edgar/data/1620463/000119312526134565/) |
| Short-term investments | [$19.1 million](https://www.sec.gov/Archives/edgar/data/1620463/000119312526352243/) | [$2.8 million](https://www.sec.gov/Archives/edgar/data/1620463/000119312526134565/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $32.3 million, plus short-term investments of $18.7 million, $51.1 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about LeonaBio

Did LeonaBio do a reverse stock split?

Our latest story on this, dated Apr 16, 2025: "Athira Pharma (now LeonaBio) wins Nasdaq Capital Market move and 180 more days". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/athira-pharma-now-leonabio-wins-nasdaq-capital-market-move-180-more/).

What is the ticker symbol of LeonaBio?

LeonaBio, Inc. trades under the ticker LONA on NASDAQ.

Where is LeonaBio listed?

LeonaBio, Inc. is listed on NASDAQ.

What is the SEC CIK of LeonaBio?

The SEC Central Index Key (CIK) for LeonaBio, Inc. is 1620463. Its filings are on SEC EDGAR.

How many shares does LeonaBio have outstanding?

9,421,663 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-14.

Which country or territory is LeonaBio listed under?

Our directory records LeonaBio, Inc. under United States.

What does LeonaBio do?

Our directory classifies LeonaBio, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of LeonaBio?

The ISIN recorded for LeonaBio, Inc. is US04746L2034.

Does aibio.space cover LeonaBio?

aibio.space lists LeonaBio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Is LeonaBio profitable?

LeonaBio, Inc. reported a net loss of $105.6 million for the fiscal year ended Dec 31, 2025, and used $45.7 million of cash in operations, per its annual report to the SEC.

How much does LeonaBio spend on research and development?

$17.5 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does LeonaBio have?

$51.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.

What is the latest LeonaBio (LONA) stock news?

Our latest story on LeonaBio, dated Sep 22, 2026: "LeonaBio Series A warrants become exercisable at $6.35 a share". LeonaBio said its Series A common warrants became exercisable on September 18, 2026 and remain exercisable until October 19, 2026, with about $146.2 million of cash if fully exercised. [Source](https://aibio.space/news/leonabio-series-warrants-become-exercisable-6-35-share/).

What is LeonaBio's latest stock offering or financing news?

Our latest financing story, dated Sep 22, 2026: "LeonaBio Series A warrants become exercisable at $6.35 a share". LeonaBio said its Series A common warrants became exercisable on September 18, 2026 and remain exercisable until October 19, 2026, with about $146.2 million of cash if fully exercised. [Source](https://aibio.space/news/leonabio-series-warrants-become-exercisable-6-35-share/).

What is LeonaBio's market cap?

We do not publish live share prices. In its annual report, LeonaBio, Inc. put the market value of shares held by non-affiliates (public float) at $9.9 million as of Jun 30, 2025.

## Investor discussion: LeonaBio

Members talk about LeonaBio (LONA). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at LeonaBio, newest first. Each line links the filing it comes from.

1. 2026-09-22 Financings Reported a financing. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1620463/000119312526397952/lona-20260918.htm)
2. 2026-08-26 Financings Reported a financing. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1620463/000119312526368288/lona-20260826.htm)
3. 2026-08-14 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1620463/000119312526352243/lona-20260630.htm)
4. 2026-01-09 Financings Reported a financing. SEC Form 8-K (Items 5.02,5.03,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1620463/000119312526008904/atha-ex99_1.htm)
5. 2025-12-18 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1620463/000119312525323692/atha-ex99_1.htm)
6. 2025-11-06 Listings Reported a reverse stock split. SEC Form 8-K (Items 2.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1620463/000119312525269506/atha-ex99_1.htm)
7. 2025-09-11 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1620463/000095017025114093/atha-ex99_1.htm)
8. 2025-08-07 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1620463/000095017025105029/atha-ex99_1.htm)
9. 2025-06-02 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1620463/000095017025080234/atha-20250529.htm)
10. 2025-05-09 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1620463/000095017025068020/atha-ex99_1.htm)
11. 2025-04-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1620463/000095017025054707/atha-20250415.htm)
12. 2025-04-14 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1620463/000114036125013769/ny20044300x2_def14a.htm)
13. 2025-04-04 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1620463/000114036125012299/ny20044300x1_pre14a.htm)
14. 2025-02-27 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1620463/000095017025029038/atha-ex99_1.htm)
15. 2025-02-27 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1620463/000095017025029069/atha-20241231.htm)
16. 2024-11-07 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1620463/000095017024123324/atha-ex99_1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:LONA on TradingView](https://www.tradingview.com/symbols/NASDAQ-LONA/).

## SEC filings and registration

- **SEC name**: LeonaBio, Inc.

- **CIK**: 1620463

- **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836)

- **US tickers**: LONA (Nasdaq)

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011

- **Phone**: (425) 620-8501

- **Shares outstanding**: 9,421,663 as of 2026-08-04 (10-Q filed 2026-08-14)

- **Former names**: Athira Pharma, Inc.; M3 Biotechnology, Inc.

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1620463/000119312526397952/lona-20260918.htm) filed 2026-09-22
- [8-K](https://www.sec.gov/Archives/edgar/data/1620463/000119312526368288/lona-20260826.htm) filed 2026-08-26
- [10-Q](https://www.sec.gov/Archives/edgar/data/1620463/000119312526352243/lona-20260630.htm) filed 2026-08-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1620463/000119312526352208/lona-20260814.htm) filed 2026-08-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1620463/000119312526279425/lona-20260622.htm) filed 2026-06-23
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/1620463/000119312526216742/lona-20260511.htm) filed 2026-05-11
- [10-Q](https://www.sec.gov/Archives/edgar/data/1620463/000119312526211898/lona-20260331.htm) filed 2026-05-07
- [8-K](https://www.sec.gov/Archives/edgar/data/1620463/000119312526211867/lona-20260507.htm) filed 2026-05-07

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001620463), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

LeonaBio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker LONA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: LeonaBio, Inc.

- **Ticker**: LONA

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: US04746L2034

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-LONA/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/leonabio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "LeonaBio (LONA) news: reverse split", 2026-10-31, https://aibio.space/companies/leonabio/